We are live on ! Find out more
SWTX

SpringWorks Therapeutics

Delisted

SWTX was delisted on the 30th of June, 2025.

142 hedge funds and large institutions have $2.86B invested in SpringWorks Therapeutics in 2021 Q3 according to their latest regulatory filings, with 21 funds opening new positions, 59 increasing their positions, 37 reducing their positions, and 11 closing their positions.

New
Increased
Maintained
Reduced
Closed

91% more first-time investments, than exits

New positions opened: 21 | Existing positions closed: 11

59% more repeat investments, than reductions

Existing positions increased: 59 | Existing positions reduced: 37

30% more call options, than puts

Call options by funds: $317K | Put options by funds: $243K

17% more funds holding in top 10

Funds holding in top 10: 67 (+1)

6% more funds holding

Funds holding: 134142 (+8)

0.56% more ownership

Funds ownership: 91.19%91.76% (+0.56%)

23% less capital invested

Capital invested by funds: $3.69B → $2.86B (-$830M)

Holders
142
Holders Change
+8
Holders Change %
+5.97%
% of All Funds
2.49%
Holding in Top 10
7
Holding in Top 10 Change
+1
Holding in Top 10 Change %
+16.67%
% of All Funds
0.12%
New
21
Increased
59
Reduced
37
Closed
11
Calls
$317K
Puts
$243K
Net Calls
+$74K
Net Calls Change
+$305K
Name Holding Trade Value Shares
Change
Change in
Stake
Legal & General Group
76
Legal & General Group
United Kingdom
$1.38M +$295K +3,829 +21%
TD Asset Management
77
TD Asset Management
Ontario, Canada
$1.36M
SG Americas Securities
78
SG Americas Securities
New York
$1.34M +$137K +1,782 +9%
UBS AM
79
UBS AM
Illinois
$1.33M
Marshall Wace
80
Marshall Wace
United Kingdom
$1.32M +$1.61M +20,893 New
Jane Street
81
Jane Street
New York
$1.32M +$1.61M +20,866 New
JP Morgan Chase
82
JP Morgan Chase
New York
$1.29M +$39.9K +518 +3%
Principal Financial Group
83
Principal Financial Group
Iowa
$1.02M +$7.86K +102 +0.6%
AIG
84
American International Group
New York
$1.01M -$29.3K -380 -2%
Royal Bank of Canada
85
Royal Bank of Canada
Ontario, Canada
$996K +$980K +12,713 +425%
HS
86
HighVista Strategies
Massachusetts
$989K +$382K +4,963 +47%
Manulife (Manufacturers Life Insurance)
87
Manulife (Manufacturers Life Insurance)
Ontario, Canada
$969K -$118K -1,532 -9%
DekaBank Deutsche Girozentrale
88
DekaBank Deutsche Girozentrale
Germany
$956K
CS
89
Credit Suisse
Switzerland
$939K +$182K +2,367 +19%
SO
90
STRS Ohio
Ohio
$932K -$23.1K -300 -2%
Natixis Advisors
91
Natixis Advisors
Massachusetts
$927K +$4.55K +59 +0.4%
ProShare Advisors
92
ProShare Advisors
Maryland
$903K -$166K -2,153 -13%
CSS
93
Cubist Systematic Strategies
Connecticut
$847K -$735K -9,544 -42%
WP
94
Woodline Partners
California
$845K -$6.33M -82,132 -86%
Voloridge Investment Management
95
Voloridge Investment Management
Florida
$823K -$3.12M -40,538 -76%
EAM
96
Erste Asset Management
Austria
$771K
VOYA Investment Management
97
VOYA Investment Management
Georgia
$724K
MIM
98
MetLife Investment Management
New Jersey
$669K
State Board of Administration of Florida Retirement System
99
State Board of Administration of Florida Retirement System
Florida
$642K +$23.1K +300 +3%
SMH
100
Sanders Morris Harris
Texas
$633K

SWTX Hedge Fund Activity: Q3 2021 in Review

142 of the 5,712 institutional investors tracked by Wall St. Rank reported a position in SpringWorks Therapeutics (SWTX) for Q3 2021, worth a combined $2.86B — down 23% from $3.69B a quarter earlier.

Buyers outnumbered sellers: 21 funds opened new SWTX positions and 11 closed out — a net gain of 10 holders — while 59 added to existing stakes and 37 trimmed.

The largest buyer was Bank of America, adding an estimated $28.3M. The largest seller was Bain Capital Life Sciences Investors, cutting an estimated $77.1M.

  • 142 institutional investors held SpringWorks Therapeutics (SWTX) as of Q3 2021, up from 134 in Q2 2021.
  • Funds reported $2.86B of SpringWorks Therapeutics stock for Q3 2021, down 23% quarter-over-quarter.
  • 21 funds opened new SpringWorks Therapeutics positions in Q3 2021 and 11 closed out, a net change of +10 holders.
  • The largest SpringWorks Therapeutics buyer in Q3 2021 was Bank of America, an estimated $28.3M added.
  • The largest SpringWorks Therapeutics seller in Q3 2021 was Bain Capital Life Sciences Investors, an estimated $77.1M sold.

Based on aggregated 13F filings for Q3 2021.